<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1285">
  <stage>Registered</stage>
  <submitdate>16/05/2006</submitdate>
  <approvaldate>29/05/2006</approvaldate>
  <actrnumber>ACTRN12606000205538</actrnumber>
  <trial_identification>
    <studytitle>Infliximab in the treatment of Polymyalgia Rheumatica</studytitle>
    <scientifictitle>Prednisolone and Infliximab for Polymyalgia Rheumatica: Evaluation of the safety and efficiacy of Infliximab in maintaining Corticosteroid-induced remission and in sparing Corticosteroids</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Polymyalgia rheumatica</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomly assigned to receive infusions of infliximab 3 mg/Kg, respectively, at weeks 0, 2, 6, 14, 22.                                                                                                                All patients will be treated with oral prednisone according to a fixed tapering protocol with a starting daily dosage of 15 mg tapered to 0 in 16 weeks. Prednisone dosage will be increased/restarted if flare-ups occurred.  Patients will be evaluated every 4 weeks during the  52 week follow-up period.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The predefined primary efficacy end point is the proportion of relapse/recurrence free patients</outcome>
      <timepoint>Measured at week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The  proportion of relapse/recurrence free patients</outcome>
      <timepoint>Measured at week 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of patients no longer taking steroids</outcome>
      <timepoint>At week 22 and at week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The total number of relapses or recurrences</outcome>
      <timepoint>During the 52-week study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The duration of prednisone therapy</outcome>
      <timepoint>During the 52-week study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The cumulative dose of prednisone</outcome>
      <timepoint>During the 52-week study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The number of patients with adverse events</outcome>
      <timepoint>During the 52-week study period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Consecutive adult patients who satisfy Healeys criteria for the diagnosis of PMR will be included in the study.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Patients previously treated with corticosteroids; 2) Patients with clinical and/or histological evidence of giant cell arteritis; 3) Uncontrolled diabetes and hypertension, infection and neoplasm;4) Active or inactive (latent) Tuberculosis (TB), evaluated by detailed medical history (including personal history of TB, possible previous contacts with TB, and family history of TB), chest X-rays (performed in the 2 months prior entering the study), and PPD test.  If any of those are positive or suggestive of TB the patient can not be enrolled.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone</concealment>
    <sequence>random permuted blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>7/02/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>51</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hospital S. Maria Nuova, Reggio Emilia Italy</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Reggio Emilia Hospital</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Centocor</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Italian Society of Rheumatology</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Italy</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Glucocorticoids have been  the treatment of choice for polymyalgia rheumatica but are commonly associated with serious adverse events even when given in lower doses.  A reliable alternative to glucocorticoids or an acceptable steroid-sparing drug has not been identified. A recent pilot study  suggested that infliximab may have a steroid-sparing effect in the treatment of polymyalgia rheumatica.
The primary purpose of this double blind,randomized, placebo controlled study is to evaluate the efficacy and safety of  infliximab in maintaining glucocorticosteroid-induced remission and in sparing corticosteroids in newly diagnosed  polymyalgia rheumatica patients.
Patients, investigators, and study personnel will be blinded to treatment assignments during the study, with the exception of the site pharmacists who prepare study medication.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethic Committee of Reggio Emilia Hospital</ethicname>
      <ethicaddress>Reggio Emilia</ethicaddress>
      <ethicapprovaldate />
      <hrec>41</hrec>
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali del Ministero della Salute Italiana</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/09/2001</ethicapprovaldate>
      <hrec>R02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>PierLuigi Macchioni</name>
      <address>Rheumatology Unit
Hospital of Reggio Emilia
V.le Risorgimento N 80
42100 Reggio Emilia</address>
      <phone>+39 0522296883</phone>
      <fax>+39 0522295836</fax>
      <email>macchioni.pierluigi@asmn.re.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Carlo Salvarani</name>
      <address>Rheumatology Unit
Hospital of Reggio Emilia
V.le Risorgimento N 80
42100 Reggio Emilia</address>
      <phone>+39 0522296616</phone>
      <fax>+39 0522295836</fax>
      <email>salvarani.carlo@asmn.re.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>